中高危肺栓塞的导管定向溶栓治疗
PRAGUE-26多中心、开放标签随机试验纳入558例中高危急性肺栓塞患者(血流动力学稳定、sPESI≥1、右心室功能障碍且肌钙蛋白或利钠肽升高),1:1随机接受阿替普酶导管定向溶栓+抗凝或单纯抗凝。主要终点(7天内全因死亡、复发肺栓塞或心肺失代偿/崩溃)溶栓组0.7%(2/280)vs 标准治疗组6.8%(19/278),RR 0.10(95%CI 0.02–0.44,P<0.001),差异主要来自心肺失代偿/崩溃减少。临床相关出血、大出血、颅内出血两组无显著差异。结论支持中高危肺栓塞在抗凝基础上加用导管定向溶栓可改善短期复合结局。
要点
- 中高危急性肺栓塞(血流动力学稳定、sPESI≥1、RV功能障碍+肌钙蛋白或利钠肽升高)患者,导管定向阿替普酶溶栓+抗凝使7天主要复合终点从6.8%降至0.7%(RR 0.10,95%CI 0.02–0.44,P<0.001)。
- 获益主要驱动因素为心肺失代偿或崩溃发生率降低,而非死亡或复发肺栓塞。
- 7天内临床相关出血溶栓组4.6% vs 单纯抗凝5.0%(P=0.85),大出血1.4% vs 2.2%(P=0.54),无显著增加。
- 颅内出血溶栓组2例(0.7%),标准治疗组0例;溶栓组30天内死亡1例,标准治疗组7天内死亡4例。
- 该试验为开放标签设计,主要终点事件数少(共21例),结论需在更多人群中验证。
适用人群与场景
- 中高危急性肺栓塞患者:血流动力学稳定(未具体定义)、简化肺栓塞严重指数(sPESI)评分≥1、右心室功能障碍且心脏肌钙蛋白或利钠肽水平升高。
- 场景为住院急性期(随机后7天内评估主要终点),原文未限定急诊或ICU。
诊断标准与关键阈值
- 中高危急性肺栓塞定义:血流动力学稳定、sPESI≥1、右心室功能障碍加心脏肌钙蛋白或利钠肽升高。
- 主要终点为随机后7天内全因死亡、复发肺栓塞或心肺失代偿/崩溃的复合终点。
- 临床相关出血采用Bleeding Academic Research Consortium定义;大出血采用Global Use of Strategies to Open Occluded Coronary Arteries指南定义。
处置流程与药物剂量
- 第一步:筛选符合中高危急性肺栓塞定义(血流动力学稳定、sPESI≥1、右心室功能障碍+肌钙蛋白或利钠肽升高)的患者。
- 第二步:随机分配至导管定向阿替普酶溶栓联合抗凝治疗组,或单纯抗凝治疗组(标准治疗)。
- 第三步:溶栓组给予阿替普酶经导管定向溶栓(原文未提及具体剂量、给药途径细节、频次或疗程)。
- 第四步:两组均接受抗凝治疗(原文未提及具体药物、剂量或疗程)。
- 第五步:随机后7天内评估主要复合终点及出血事件。
红旗征与不能漏的情况
- 心肺失代偿或崩溃:主要终点事件主要由此驱动,溶栓组发生率低于单纯抗凝组。
- 颅内出血:溶栓组2例(0.7%),标准治疗组0例,需警惕。
- 大出血:溶栓组1.4%(4例),标准治疗组2.2%(6例)。
- 临床相关出血:溶栓组4.6%(13例),标准治疗组5.0%(14例)。
研究设计与关键结果
- 研究类型:多中心、开放标签、随机对照试验(PRAGUE-26,NCT05493163),共558例患者随机,溶栓组280例,标准治疗组278例。
- 人群:中高危急性肺栓塞,中位年龄64岁,女性40.9%。
- 干预与对照:导管定向阿替普酶溶栓+抗凝 vs 单纯抗凝。
- 主要终点:7天内全因死亡、复发肺栓塞或心肺失代偿/崩溃复合终点,溶栓组2例(0.7%)vs 标准治疗组19例(6.8%),RR 0.10(95%CI 0.02–0.44),P<0.001。
- 关键次要终点:7天内临床相关出血4.6% vs 5.0%(P=0.85);大出血1.4% vs 2.2%(P=0.54);颅内出血2例(0.7%)vs 0例。
- 死亡:溶栓组30天内死亡1例,标准治疗组7天内死亡4例。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机对照试验(RCT)。
- 资助:捷克共和国卫生部等。
- 局限:开放标签设计;主要终点事件总数少(21例);单次试验结果需外部验证;原文未提及样本量计算依据或中期分析。
对床旁实践的改变
- 对于血流动力学稳定但sPESI≥1且存在右心室功能障碍伴肌钙蛋白或利钠肽升高的中高危急性肺栓塞患者,可考虑在抗凝基础上加用导管定向阿替普酶溶栓以降低7天内死亡、复发肺栓塞或心肺失代偿/崩溃的复合风险。
- 该策略不适用于原文未纳入的人群(如血流动力学不稳定或sPESI<1者),具体排除标准原文未提及。
- 需权衡颅内出血风险(溶栓组0.7% vs 0%),尽管大出血和临床相关出血无显著增加。
- 原文未提供阿替普酶剂量、抗凝方案细节,不能据此制定具体给药方案。
指南或共识出处
- PRAGUE-26 trial; ClinicalTrials.gov number NCT05493163; EudraCT number 2022-002218-18; European Union Clinical Trials number 2024-516144-25-00.
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether catheter-directed thrombolysis improves clinical outcomes in patients with intermediate-high-risk pulmonary embolism, as compared with anticoagulation alone, is uncertain.
METHODS: In this multicenter, open-label, randomized trial, we randomly assigned patients with intermediate-high-risk acute pulmonary embolism (defined by hemodynamic stability, a simplified Pulmonary Embolism Severity Index score of ≥1, and right ventricular dysfunction plus an elevated level of cardiac troponin or natriuretic peptide) in a 1:1 ratio to receive catheter-directed thrombolysis with alteplase plus anticoagulation therapy (thrombolysis group) or anticoagulation therapy alone (standard-care group). The primary outcome was a composite of death from any cause, recurrence of pulmonary embolism, or cardiorespiratory decompensation or collapse within 7 days after randomization. Secondary outcomes included clinically relevant bleeding as defined by the Bleeding Academic Research Consortium, major bleeding as defined in the Global Use of Strategies to Open Occluded Coronary Arteries guidelines, and intracranial hemorrhage.
RESULTS: A total of 558 patients underwent randomization; 280 were assigned to the thrombolysis group, and 278 to the standard-care group. The median age was 64 years, and 40.9% were female. A primary-outcome event occurred in 2 patients (0.7%) in the thrombolysis group and in 19 patients (6.8%) in the standard-care group (relative risk, 0.10; 95% confidence interval, 0.02 to 0.44; P<0.001); this difference was driven mainly by the lower incidence of cardiorespiratory decompensation or collapse in the thrombolysis group. By day 7, clinically relevant bleeding had occurred in 13 patients (4.6%) in the thrombolysis group and in 14 patients (5.0%) in the standard-care group (P = 0.85); major bleeding in 4 (1.4%) and 6 (2.2%), respectively (P = 0.54); and intracranial hemorrhage in 2 (0.7%) and none. One patient in the thrombolysis group died within 30 days, and 4 patients in the standard-care group died within 7 days.
CONCLUSIONS: Among patients with intermediate-high-risk acute pulmonary embolism, catheter-directed thrombolysis with alteplase plus anticoagulation therapy led to a lower risk of death from any cause, recurrent pulmonary embolism, or cardiorespiratory decompensation or collapse within 7 days after randomization than anticoagulation therapy alone. (Funded by the Ministry of Health of the Czech Republic and others; PRAGUE-26 ClinicalTrials.gov number, NCT05493163; EudraCT number, 2022-002218-18; European Union Clinical Trials number, 2024-516144-25-00.).
参考来源
- Kroupa J, Radvan M, Mrozek J, et al. Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism. N Engl J Med. 2026. PMID: 42678032. doi:10.1056/NEJMoa2608012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。